Drug Profile
Research programme: bispecific antibodies - Immune Pharmaceuticals
Alternative Names: Tetravalent bsAb - Immune Pharmaceuticals; Tetravalent IgG1-like bispecific antibody - Immune PharmaceuticalsLatest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Immune Pharmaceuticals Inc
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action B-cell maturation antigen modulators; OX40 receptor modulators; Programmed cell death-1 ligand-1 modulators; Programmed cell death-1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Renal cell carcinoma
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Cancer in USA (Parenteral) (Immune Pharmaceuticals website; August 2023)
- 31 Aug 2023 Discontinued - Preclinical for Renal cell carcinoma in France (Parenteral) (Immune Pharmaceuticals website; August 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Renal-cell-carcinoma in France (Parenteral)